Castleark Management’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
Castleark Management's TVTX Position: Q3 2026 in Review
Castleark Management opened a new position in Travere Therapeutics (TVTX) in Q3 2026: 57,760 shares worth $3.4M. The stake represents 0.09% of the portfolio and ranks #183 among its holdings. This is a return to the name: Castleark Management previously reported a position in TVTX as recently as Q3 2015.
Castleark Management first reported a position in TVTX in Q2 2015 and has held it in 3 quarters since. The position peaked at $8.08M in Q2 2015. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.
- Castleark Management held 57,760 shares of Travere Therapeutics worth $3.4M as of Q3 2026.
- Travere Therapeutics was a new Castleark Management position in Q3 2026.
- Travere Therapeutics made up 0.09% of Castleark Management's portfolio in Q3 2026, its #183 holding.
- Castleark Management first reported a position in Travere Therapeutics in Q2 2015 and has held it in 3 quarters since.
- Castleark Management's Travere Therapeutics position peaked at $8.08M in Q2 2015.
- 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.
Based on Castleark Management's 13F filing for Q3 2026, filed 16 Nov 2026.